Our activity sensors are administered to patients and tailor-made to query the activity of key biological targets such as proteases – a class of enzymes that drive critical disease pathways. We are applying sophisticated machine learning algorithms to develop a proprietary, whole-genome database of enzymes and sensors capable of targeting all clinically-relevant proteases. Our technology platform is extendable to multifunctional enzymes including kinases, glycases, and lipases. Our lead program is Non-Alcoholic Steatohepatitis (NASH), estimated to impact 16 million people in the U.S. and over 100 million worldwide. Our development pipeline features programs in liver and lung diseases (representing over $5 billion in total addressable markets) with preclinical validation in 10+ additional diseases. Glympse has a creative business model that blends the best of a diagnostic development and regulatory pathway, therapeutics go-to-market model, and a biology-rich data engine.